[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cartilage-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cartilage-injury":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,105,132,159,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100534447","long-term-outcome-evaluation-of-patients-undergoing-autologous-chondrocyte-transplantation-delivered-on-biomaterial-100534447",false,"NCT06238947","Long-term Outcome Evaluation of Patients Undergoing Autologous Chondrocyte Transplantation Delivered on Biomaterial","LONG-TERM EVALUATION OF OUTCOMES OF PATIENTS UNDERGOING AUTOLOGOUS CHONDROCYTE TRANSPLANTATION DELIVERED ON BIOMATERIAL (HYALOGRAFT C) Prospective Observational Study","Inclusion Criteria:\n\n* Patients who underwent autologous chondrocyte transplantation surgery delivered on biomaterial (Hyalograft C) from 1999 to 2006 at the Rizzoli Orthopaedic Institute who met the following criteria at the time of surgery:\n* Full-thickness chondral defects (Outerbridge grade III - IV) and osteochondral defects at the femoral condyles, trochlea, patella and tibial plateau.\n* Patients aged between 14 and 60 years at the time of surgery.\n* Male and female sex.\n\nExclusion Criteria:\n\n* Patients no longer available","ALL","14 Years","60 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Chondro-Long study is prospective observational study for a long-term clinical evaluation (follow-up up to 25 years) in patients treated with autologous chondrocyte transplantation delivered on biomaterial for full-thickness chondral defects (Outerbridge grade III - IV) at the level of femoral condyles, trochlea, patella and tibial plateau.\n\nThe aim of the study is to collect long-term clinical data from the case series of patients surgically treated from 1999 to 2006 with autologous chondrocyte transplantation delivered on biomaterial for full-thickness chondral defects (Outerbridge grade III - IV) or osteochondral defects at the level of femoral condyles, trochlea, patella, and tibial plateau. The objective of the study is to demonstrate the efficacy of this long-term cartilage regeneration technique (follow-up up to 25 years) in improving patient symptomatology and functional capacity",[25,26],"Cartilage Injury","Cartilage Disease",[28,29],"autologous chondrocyte transplantation","osteochondral defects","NOT_YET_RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":21},"2026-09",{"date":38,"type":21},"2027-02",{"name":40,"class":41},"Istituto Ortopedico Rizzoli","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443","NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons",{"count":50,"type":21},100,"INTERVENTIONAL",[53],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,25],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","2026-05-01",{"date":98,"type":34},"2026-05-05",{"date":100,"type":21},"2026-08",{"date":102,"type":21},"2035-12",{"name":104,"class":41},"Jay C. Buckey Jr.",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":51,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100600177","tissue-engineered-cartilage-to-repairing-articular-cartilage-defects-100600177","NCT07094100","Tissue Engineered Cartilage to Repairing Articular Cartilage Defects","Clinical Study of Cartilage Constructed by Autologous Bone Marrow Mesenchymal Stem Cells in Repairing Articular Cartilage Defects","Inclusion Criteria:\n\n1. The patients' age ranges from 18 to 65 years old, and gender is not restricted;\n2. The imaging results show that the epiphyseal growth is mature;\n3. The defects or localized injuries of joint cartilage caused by trauma or other reasons;\n4. The injured area is the distal weight-bearing surface of the femoral condyle of the knee joint, with no more than 4 lesions, and there is no injury to the cruciate ligaments;\n5. The patients voluntarily sign and provide a written informed consent form and are willing to closely cooperate with the doctor's strict postoperative rehabilitation program.\n\nExclusion Criteria:\n\n1. The patient is extremely overweight, with a body mass index greater than 35;\n2. The lower limb alignment is valgus by more than 10° and varus by more than 5°;\n3. Multiple ligament injuries;\n4. There are numerous bad habits such as heavy smoking, drug abuse, and excessive alcohol consumption;\n5. Has undergone open knee joint surgery within the past six months;\n6. Has severe joint stiffness or fibrosis;\n7. Has an allergic constitution or a history of allergic reactions to collagen;\n8. Has mental abnormalities;\n9. Cannot or is unwilling to undergo rehabilitation training;\n10. Has primary cardiovascular diseases, lung diseases, endocrine and metabolic disorders, or other serious diseases that affect their daily life, such as tumors or AIDS;\n11. Pregnant or lactating women, or those planning to conceive during the trial period;\n12. Other acute or chronic diseases, for which the researchers consider surgery to be inappropriate.","18 Years","65 Years",{"count":115,"type":21},30,[117],"NA","The joint cartilage constructed by combining bone marrow mesenchymal stem cells with three-dimensional materials has achieved the goal of repairing joint cartilage.",[25,120],"OA Knee","RECRUITING","2026-04-28",{"date":124,"type":34},"2026-05-04",{"date":126,"type":21},"2026-04-20",{"date":128,"type":21},"2028-12",{"name":130,"class":41},"The First Affiliated Hospital of Xinxiang Medical College",1,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":113,"enrollmentInfo":140,"targetDuration":4,"studyType":51,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":158},"100542562","the-hyalex-first-in-human-study-100542562","NCT06344481","The Hyalex First-in-Human Study","A Prospective, Multicenter, Single-Arm, 2-Phase First-in-Human Feasibility Study of the HYALEX® Cartilage System","Inclusion Criteria - Phase 1\n\n1. 21-65 years.\n2. Body Mass Index (BMI) ≤ 35.\n3. Singular treatable joint surface lesion, ICRS Grade 3 or 4, located on the medial or lateral femoral condyle.\n4. Symptomatic, single treatable area 1 - 3.8cm2.\n5. Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale score between 20 and 65.\n6. Stable knee.\n7. Non-responsive to a minimum of 3 weeks of conservative treatment, consisting of non-steroidal anti-inflammatory drugs and\u002For physical therapy.\n\nInclusion Criteria - Phase 2\n\n1. 21-65 years.\n2. Body Mass Index (BMI) ≤ 35.\n3. Up to three treatable joint surface lesion(s), ICRS Grade 3 or 4, located on the medial or lateral femoral condyle(s).\n4. Symptomatic total treatable area 1 - 10cm2.\n5. Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale score between 20 and 65.\n6. Stable knee.\n7. Non-responsive to a minimum of 3 weeks of conservative treatment, consisting of non-steroidal anti-inflammatory drugs and\u002For physical therapy.\n\nExclusion Criteria - Phase 1 \\& 2\n\nHYALEX Implant, Surgical Technique, and Lesion Site Exclusions:\n\n1. Known allergy to polyurethanes, bone cement, acrylic, or titanium.\n2. Lack of 2mm of healthy cartilage (ICRS Grade 0 or 1) and 2mm of vital bone wall on all sides of the implant site.\n3. Osteochondral defect affecting subchondral bone more than 11mm in depth from adjacent non-defect articular surface.\n4. Bipolar cartilage lesions involving patellar or tibial lesions ICRS Grade 3 - 4 opposite the lesion intended for treatment.\n5. Insufficient bone stock or bone density determined intra-operatively preventing implant press fit.\n\nPatient Orthopaedic Health Exclusions:\n\n1. Kellgren and Lawrence (KL) grade 3 or 4 on standing radiographs as defined:\n2. Hip-knee-ankle (HKA) angle of greater than +\u002F- 5 degrees (varus or valgus malalignment \\> 5 degrees) on standing X-ray.\n3. Lack of normally functioning contralateral knee that restricts activity.\n4. Insufficiency fracture of the femoral condyle or tibial plateau.\n5. Recent Osteochondritis Dissecans within 1 year.\n6. Diagnosis of a concomitant knee injury which the investigator believes may interfere with study participation or confound effectiveness assessment.\n7. Any known systemic cartilage and\u002For bone disorder, such as but not limited to osteoporosis, chondrodysplasia or osteogenesis imperfecta.\n8. A symptomatic musculoskeletal condition in the lower limbs that could impede effectiveness measurements in the target knee.\n9. Any known tumor of the treatment knee.\n10. Prior radiation therapy to the knee joint.\n11. Clinically significant or symptomatic vascular or neurological disorder of the lower extremities affecting gait or function.\n12. Untreated ACL and\u002For PCL deficiency or complex ligamentous instability of the study knee according to IKDC Grade C (abnormal) or D (severely abnormal).\n\nPrevious Surgery and Intervention Exclusions:\n\n1. Previous surgery in the past 6 months on the index knee except for:\n\n   1. Diagnostic knee arthroscopy and\u002For debridement \u002F chondroplasty, and\n   2. Meniscectomy\n2. Previous intra-articular injections, including HA and steroids, within the last 3 months prior to the date of surgery.","21 Years",{"count":141,"type":21},15,[117],"The Hyalex First-in-Human Study is a prospective, multicenter, open-label, single-arm, 2-phase, first-in-human study to evaluate the safety and technical performance of the HYALEX Knee Cartilage System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment.",[25],[146,147,148],"Knee","Cartilage","Lesion","2025-06-26",{"date":151,"type":34},"2025-06-29",{"date":153,"type":34},"2024-03-07",{"date":36,"type":21},{"name":156,"class":157},"Hyalex Orthopaedics, Inc.","INDUSTRY",2,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":18,"enrollmentInfo":167,"targetDuration":4,"studyType":51,"phases":169,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":131},"100522431","effect-of-platelet-rich-plasma-prp-injection-on-knee-osteoarthritis-100522431","NCT06082531","Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis","Therapeutic Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis and Periarticular Tissue Injury","Inclusion Criteria:\n\n* The age range of the participants was 20 to 60 years old. Through a comprehensive clinical and imaging examination, it was conclusively determined that the individuals had knee osteoarthritis or experienced injuries to the cart, and meniscus surrounding the knee joint.\n* The preoperative routine tests and examinations revealed no contraindications.\n* Revised sentence: \"Informed consent of the patient\n\nExclusion Criteria:\n\n* The platelet count or function exhibits significant abnormalities、Systemic infection transmitted through the bloodstream.\n* Prolonged usage of anti-inflammatory drugs and systemic corticoid administration.\n* In injection site or damage to the skin.\n* Patients with tumors or undergoing radiotherapy and chemotherapy.\n* Pregnant or breastfeeding women.\n* Individuals with mental illnesses who are unable to cooperate with follow-up procedures.\n* Contraindications for MRI、Patients or their families do consent to participate in the study.\n* Other circumstances that render participation in the study unsuitable.","20 Years",{"count":168,"type":21},300,[117],"To evaluate the safety and effectiveness of PRP injection therapy in the repair of osteoarthritis and periarticular soft tissue injury through a single-center, exploratory clinical study, and to provide a more reliable basis for the treatment of joint injury.",[172,173,174,25],"Platelets-rich Plasma","Osteoarthritis Knees Both","Meniscus Disorder",[176,177,25,178],"platelets-rich plasma","Osteoarthritis","Meniscus Injury","2025-04-06",{"date":181,"type":34},"2025-04-09",{"date":183,"type":34},"2023-09-01",{"date":185,"type":21},"2025-12-31",{"name":187,"class":41},"Xijing Hospital",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":196,"sex":16,"minAge":197,"maxAge":112,"enrollmentInfo":198,"targetDuration":4,"studyType":51,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":158},"100533032","casting-and-rehabilitation-versus-supervised-neglect-for-osteochondral-lesions-of-the-talus-in-the-pediatric-population-100533032","NCT06220539","CAsting and REhabilitation Versus Supervised Neglect for Osteochondral Lesions of the Talus in the Pediatric Population","CAsting and REhabilitation Versus Supervised Neglect for Osteochondral Lesions of the Talus in the Pediatric Population: The CARE Study, A Multicenter, Stratified, Block-Randomized Controlled Trial","CARE","Inclusion Criteria:\n\n* Symptomatic, osteochondral lesion of the talus\n* Diagnosed on Computed Tomography (CT)\n* Open physes of the distal tibia confirmed by a specialized musculoskeletal or pediatric radiologist\n* Age ≥4 and ≤18\n\nExclusion Criteria:\n\n* acute traumatic lesions\n* surgically treated OLTs\n* systemic diseases that can influence cartilage conditions (such as hemophilia)",true,"4 Years",{"count":199,"type":21},76,[117],"Rationale: OCLs (osteochondral lesions) of the talus can be congenital or can occur after trauma or in patients with juvenile idiopathic arthritis (JIA). The main complaint of an OCL is pain during weightbearing activities. Therefore, these lesions have significant impact on the health status of patients.\n\nObjective: The aim of this study is to optimize the treatment for skeletally immature patients with an osteochondral lesion. The hypothesis is that a period of immobilization and supervised rehabilitation will lead to better clinical and radiological outcomes compared with standard care which is a ''skill-full'' neglect.\n\nStudy design: Observational comparative study\n\nStudy population: Skeletally immature children with an osteochondral lesion of the talus diagnosed on CT.\n\nIntervention: Patients in the intervention group will undergo an 8-week period of casting and walking on crutches. Afterwards, they will receive a protocolled period of rehabilitation under supervision of a physical therapist. The control group will have the standard care as treatment.\n\nMain study parameters\u002Fendpoints: the main study outcome is the difference between the two groups on the OxAFQ-C. Secondary study outcomes are radiologic changes in terms of morphology and lesion size, NRS during weight bearing and quality of life measured with a Peds-QL, EQ-5D-y and AAS.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: the burden that patients will have is mainly the time that they have to spent on fulfilling the questionnaires.",[25,203,204,205,206],"Orthopedic Disorder","Skeletal Injury","Rehabilitation","Physiotherapy","2024-01-13",{"date":209,"type":34},"2024-01-24",{"date":211,"type":21},"2024-02-01",{"date":213,"type":21},"2027-07-01",{"name":215,"class":41},"Tristan Buck"]